Finanzen von Hemab Therapeutics Holdings Inc (COAG)COAGHemab Therapeutics Holdings Inc

In the context of the broader market, COAG competes directly with industry leaders such as ADMA and KLRA. With a market capitalization of $2.09B, it holds a significant position in the sector. When comparing efficiency, COAG's gross margin of N/A stands against ADMA's 69.31% and KLRA's N/A. Such benchmarking helps identify whether Hemab Therapeutics Holdings Inc is trading at a premium or discount relative to its financial performance.

Hemab Therapeutics reported a net loss of $24.2 million in Q2 2026, translating to an EPS of -0.80, which is a significant increase from the previous year's loss of $12.2 million. The company has cash reserves of $457.5 million, expected to fund operations into 2029.